ADM PROTEXIN LIMITED – Trademark Portfolio
Entity Type: 99
ADM PROTEXIN LIMITED holds 18 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 18 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 3 Nice Classification classes. Currently, 8 trademarks are registered and 2 are pending. Notable registered marks include NUVO, MIGRÉA, BIO-KULT, PROTEXIN, and BIO-KULT LOVE YOUR MICROBIOME. The owner is based in SOMERSET.
LOPEN HEAD
SOUTH PETHERTON
SOMERSET TA13 5JH , GB
Showing of trademarks Trademarks
Trademark Classifications
ADM PROTEXIN LIMITED's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does ADM PROTEXIN LIMITED have?
ADM PROTEXIN LIMITED has 18 U.S. trademarks filed with the USPTO. Of these, 8 registered, 2 pending, 4 abandoned, 1 cancelled.
What trademark classes does ADM PROTEXIN LIMITED file in?
ADM PROTEXIN LIMITED files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business), Class 1 (Chemicals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are ADM PROTEXIN LIMITED's most well-known trademarks?
ADM PROTEXIN LIMITED's registered trademark portfolio includes well-known marks such as NUVO, MIGRÉA, BIO-KULT, PROTEXIN, and BIO-KULT LOVE YOUR MICROBIOME. These are among 8 currently registered trademarks in the portfolio.
What is ADM PROTEXIN LIMITED's trademark registration success rate?
ADM PROTEXIN LIMITED has a 62% trademark registration rate, with 8 out of 13 resolved applications resulting in successful registration. Currently, 2 applications are pending review.